• 1
    Sato N, Koeda K, Ikeda K, et al. Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg. 2002; 236: 184190.
  • 2
    Herrstedt J, Aapro MS, Smyth JF, Del Favero A. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer. 1998; 6: 204214.
  • 3
    Münstedt K, Müller H, Blauth-Eckmeyer E, Stenger K, Zygmunt M, Vahrson H. Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. Br J Cancer. 1999; 79: 637639.
  • 4
    Garcia-del-Muro X, Vadell C, Perez Manga G, et al. Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. Eur J Cancer. 1998; 34: 193195.
  • 5
    Perez EA. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting. Cancer J Sci Am. 1998; 4: 7277.
  • 6
    Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol. 1998; 9: 639645.
  • 7
    Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002; 249: 13571369.
  • 8
    Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg. 2003; 98: 342349.
  • 9
    Maranzano E. Radiation-induced emesis: a problem with many open questions. Tumori. 2001; 87: 213218.
  • 10
    Kolb EA, Steinherz PG. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia. 2003; 17: 19671972.
  • 11
    Shapiro M, Wasik MA, Junkins-Hopkins JM, et al. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. Am J Hematol. 2003; 74: 4651.
  • 12
    Wiseman LR, Spencer CM. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging. 1997; 10: 473485.
  • 13
    Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV. Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol. 1998; 69: 122124.
  • 14
    Cao TM, Negrin RS, Stockerl-Goldstein KE, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000; 6: 387394.
  • 15
    Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol. 1989; 25: 18231829.
  • 16
    Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985; 69: 751754.
  • 17
    Iversen HG, Hjort GH. The influence of corticoid steroids on the frequency of spleen metastases in patients with breast cancer. Acta Pathol Microbiol Scand. 1958; 44: 205212.
  • 18
    Sherlock P, Hartmann WH. Adrenal steroids and the pattern of metastases of breast cancer. JAMA. 1962; 181: 313317.
  • 19
    Haid M. Steroid antiemesis may be harmful. N Engl J Med. 1981; 304: 1237.
  • 20
    Herr I, Ucur E, Herzer K, et al. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 2003; 63: 31123120.
  • 21
    Frauman AG. An overview of the adverse reactions to adrenal corticosteroids. Adverse Drug React Toxicol Rev. 1996; 15: 203206.
  • 22
    Mattano LA Jr., Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000; 18: 32623272.
  • 23
    Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001; 19: 30663072.
  • 24
    Murphy P, Alexander P, Senior PV, Fleming J, Kirkham N, Taylor I. Mechanisms of organ selective tumour growth by bloodborne cancer cells. Br J Cancer. 1988; 57: 1931.
  • 25
    Wolf J, Spear P, Yesner R, Patno ME. Nitrogen mustard and steroid hormones in treatment of inoperable bronchogenic carcinoma. Am J Med. 1960; 29: 10081016.
  • 26
    Rasmuson T, Ljungberg B, Grankvist K, Jacobsen J, Olsson T. Increased serum cortisol levels are associated with high tumour grade in patients with renal cell carcinoma. Acta Oncol. 2001; 40: 8387.
  • 27
    Powell CB, Mutch DG, Kao MS, et al. Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity. Cancer. 1990; 65: 466472.
  • 28
    Gascoyne DM, Kypta RM, Vivanco MM. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL. J Biol Chem. 2003; 278: 1802218029.
  • 29
    Zachos G, Varras M, Koffa M, Ergazaki M, Spandidos DA. Glucocorticoid and estrogen receptors have elevated activity in human endometrial and ovarian tumors as compared to the adjacent normal tissues and recognize sequence elements of the H-ras proto-oncogene. Jpn J Cancer Res. 1996; 87: 916922.
  • 30
    AderE, FeltenDL, CohenN, editors. Psychoneuroimmunology. 3rd edition. San Diego: Academic Press, 2001.
  • 31
    Miller GE, Cohen S, Rabin BS, Skoner DP, Doyle WJ. Personality and tonic cardiovascular, neuroendocrine, and immune parameters psychoneuroendocrinology and psychoneuroimmunology of cancer: plausible mechanisms worth pursuing? Brain Behav Immun. 2003; 17 Suppl 1: 8491.
  • 32
    Antoni MH. Psychoneuroimmunology and cancer: fact or fiction? Eur J Cancer. 1999; 35A: 16031607.
  • 33
    von Georgi R, Schubert K, Grant P, Münstedt K. Post-therapy surveillance and after-care in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2003; 111: 189196.
  • 34
    Joyce RA, Chervenick PA. Corticosteroid effect of granulopoiesis in mice after cyclophosphamide. J Clin Invest. 1977; 60: 277283.
  • 35
    Kriegler AB, Bernardo D, Verschoor SM. Protection of murine bone marrow by dexamethasone during cytotoxic chemotherapy. Blood. 1994; 83: 6571.
  • 36
    Rinehart JJ, Delamater EW, Keville L, Measel J. Corticosteroid modulation of interleukin-1 hematopoetic effects and toxicity in a murine system. Blood. 1994; 84: 14571463.
  • 37
    Rinehart JJ, Keville L, Measel J, Spiekerman AM, Burke K. Corticosteroid alterations of carboplatin-induced hematopoietic toxicity in a murine model. Blood. 1995; 86: 44934499.
  • 38
    Rinehart JJ, Keville LR. Reduction in carboplatin hematopoietic toxicity in tumor bearing mice: comparative mechanisms and effects of interleukin-1 and corticosteroids. Cancer Biother Radiopharm. 1997; 12: 101109.
  • 39
    Rinehart J, Keville L, Neidhart J, et al. Hematopoietic protection by dexamethasone or granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients treated with carboplatin and ifosfamide. Am J Clin Oncol. 2003; 26: 448458.
  • 40
    Hensleigh PA, Herzenberg LA, Lipman SH, et al. Transient immunologic effects of betamethasone in human pregnancy after suppression of preterm labor. Am J Reprod Immunol. 1983; 4: 8387.
  • 41
    Kadanali S, Ingec M, Kucukozkan T, Borekci B, Kumtepe Y. Changes in leukocyte, granulocyte and lymphocyte counts following antenatal betamethasone administration to pregnant women. Int J Gynaecol Obstet. 1997; 58: 269274.
  • 42
    Mushkat Y, Ascher-Landsberg J, Keidar R, Carmon E, Pauzner D, David MP. The effect of betamethasone versus dexamethasone on fetal biophysical parameters. Eur J Obstet Gynecol Reprod Biol. 2001; 97: 5052.
  • 43
    Xu MJ, Fang GE, Liu YJ, Song LN. Effects of glucocorticoid on proliferation, differentiation, and glucocorticoid receptor expression in human ovarian carcinoma cell line 3AO. Acta Pharmacol Sin. 2002; 23: 819823.
  • 44
    Xu M, Song L, Wang Z. Effects of dexamethasone on glucocorticoid receptor expression in a human ovarian carcinoma cell line 3AO. Chin Med J (Engl). 2003; 116: 392395.
  • 45
    Xia B, Lu J, Wang G. Glucocorticoid modulation of extracellular signal-regulated protein kinase 1/2 and p38 in human ovarian cancer HO-8910 cells. Chin Med J (Engl). 2003; 116: 753756.
  • 46
    Akakura K, Suzuki H, Ueda T, et al. Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate. 2003; 56: 106109.
  • 47
    Nishimura K, Nonomura N, Satoh E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst. 2001; 93: 17391746.
  • 48
    Gametchu B, Watson CS. Correlation of membrane glucocorticoid receptor levels with glucocorticoid-induced apoptotic competence using mutant leukemic and lymphoma cells [sic] lines. J Cell Biochem. 2002; 87: 133146.
  • 49
    Theocharis S, Kouraklis G, Margeli A, et al. Glucocorticoid receptor (GR) immunohistochemical expression is correlated with cell cycle-related molecules in human colon cancer. Dig Dis Sci. 2003; 48: 17451750.